"Receptor, Endothelin B" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subtype of endothelin receptor found predominantly in the KIDNEY. It may play a role in reducing systemic ENDOTHELIN levels.
| Descriptor ID |
D044023
|
| MeSH Number(s) |
D12.776.543.750.695.220.200 D12.776.543.750.750.320.200
|
| Concept/Terms |
Receptor, Endothelin B- Receptor, Endothelin B
- Endothelin B Receptor
- Endothelin B Receptors
- Receptors, Endothelin B
Receptor, Endothelin B, Type 2- Receptor, Endothelin B, Type 2
- Endothelin B-2 Receptors
- Endothelin B 2 Receptors
- Receptors, Endothelin B-2
- Endothelin B-2 Receptor
- Endothelin B 2 Receptor
- Receptor, Endothelin B-2
|
Below are MeSH descriptors whose meaning is more general than "Receptor, Endothelin B".
Below are MeSH descriptors whose meaning is more specific than "Receptor, Endothelin B".
This graph shows the total number of publications written about "Receptor, Endothelin B" by people in this website by year, and whether "Receptor, Endothelin B" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptor, Endothelin B" by people in Profiles.
-
Genome-wide association studies for two exterior traits in Chinese Dongxiang spotted pigs. Anim Sci J. 2018 Jun; 89(6):868-875.
-
Interacting hypoxia and endothelin in the diabetic kidney: therapeutic options. Am J Physiol Renal Physiol. 2018 05 01; 314(5):F699-F701.
-
Endothelin-1-induced endothelial mesenchimal transition via endothelin type B receptor stimulation: implication for chronic kidney disease. J Hypertens. 2017 06; 35(6):1329-1330.
-
Renal and systemic effects of chronic blockade of ET(A) or ET(B) receptors in normal rats and animals with experimental heart failure. J Cardiovasc Pharmacol. 2004 Nov; 44 Suppl 1:S54-8.